Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patients with Rett syndrome; Phase II clinical trial for the treatment of Parkinson's disease; and preclinical clinical trials to treat epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. The company's drug candidate also comprises ANAVEX 3-71, which is in Phase I clinical trial for the treatment of frontotemporal dementia and other dementia indications; and preclinical clinical trials for the treatment of neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases. Its preclinical drug candidates include ANAVEX 1-41, a sigma-1 receptor agonist for the treatment of depression, stroke, Parkinson's, and Alzheimer's diseases; ANAVEX 1066, a mixed sigma-1/sigma-2 ligand for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.

Anavex Life Sciences Corp.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

NEW YORK, DEC. 18, 2025 (GLOBE NEWSWIRE) -- ANAVEX LIFE SCIENCES CORP. (ANAVEX OR THE COMPANY) (NASDAQ: AVXL), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING INNOVATIVE TREATMENTS FOR ALZHEIMER'S DISEASE, PARKINSON'S DISEASE, SCHIZOPHRENIA, NEURODEVELOPMENTAL, NEURODEGENERATIVE, AND RARE DISEASES, INCLUDING RETT SYNDROME, AND OTHER CENTRAL NERVOUS SYSTEM (CNS) DISORDERS, TODAY ANNOUNCED THAT IT HAS REQUESTED THE EUROPEAN MEDICINES AGENCY (EMA) TO RE-EXAMINE ITS OPINION ON BLARCAMESINE FOR THE TREATMENT OF EARLY ALZHEIMER'S DISEASE.

ANAVEX LIFE SCIENCES SUBMITTED REQUEST FOR EMA TO RE-EXAMINE ITS OPINION

NEW YORK, DEC. 12, 2025 (GLOBE NEWSWIRE) -- ANAVEX LIFE SCIENCES CORP. (ANAVEX OR THE COMPANY) (NASDAQ: AVXL), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING INNOVATIVE TREATMENTS FOR ALZHEIMER'S DISEASE, PARKINSON'S DISEASE, SCHIZOPHRENIA, NEURODEVELOPMENTAL, NEURODEGENERATIVE, AND RARE DISEASES, INCLUDING RETT SYNDROME, AND OTHER CENTRAL NERVOUS SYSTEM (CNS) DISORDERS, TODAY PROVIDES AN UPDATE ON THE REGULATORY REVIEW IN THE EU FOR BLARCAMESINE TO TREAT EARLY ALZHEIMER'S DISEASE.

ANAVEX LIFE SCIENCES PROVIDES UPDATE ON REGULATORY REVIEW IN THE EU FOR BLARCAMESINE TO TREAT EARLY ALZHEIMER'S DISEASE

NEW YORK , DEC. 11, 2025 /PRNEWSWIRE/ -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF ANAVEX LIFE SCIENCES CORP. ("ANAVEX" OR THE "COMPANY") (NASDAQ: AVXL).SUCH INVESTORS ARE ADVISED TO CONTACT DANIELLE PEYTON AT NEWACTION@POMLAW.COMOR 646-581-9980, EXT.

INVESTOR ALERT: POMERANTZ LAW FIRM INVESTIGATES CLAIMS ON BEHALF OF INVESTORS OF ANAVEX LIFE SCIENCES CORP. - AVXL

NEW YORK, NOV. 26, 2025 (GLOBE NEWSWIRE) -- ANAVEX LIFE SCIENCES CORP. (ANAVEX OR THE COMPANY) (NASDAQ: AVXL), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING INNOVATIVE TREATMENTS FOR ALZHEIMER'S DISEASE, PARKINSON'S DISEASE, SCHIZOPHRENIA, NEURODEVELOPMENTAL, NEURODEGENERATIVE, AND RARE DISEASES, INCLUDING RETT SYNDROME, AND OTHER CENTRAL NERVOUS SYSTEM (CNS) DISORDERS, TODAY ANNOUNCED THAT IT WILL PRESENT ONE ORAL LATE BREAKING COMMUNICATION AND TWO POSTER PRESENTATIONS FEATURING BLARCAMESINE AT THE 18TH CLINICAL TRIALS ON ALZHEIMER'S DISEASE (CTAD) CONFERENCE, BEING HELD IN SAN DIEGO, CALIFORNIA FROM DECEMBER 1-4, 2025. DETAILS: PRESENTATION #1 (LB11) TITLE: ORAL BLARCAMESINE PHASE IIB/III TRIAL CONFIRMS IDENTIFIED PRECISION MEDICINE PATIENT POPULATION  SIGNIFICANT BROAD CLINICAL AND QUALITY OF LIFE IMPROVEMENTS FOR EARLY ALZHEIMER'S DISEASE PATIENTS PRESENTER: MARWAN NOEL SABBAGH, MD, PROFESSOR OF NEUROLOGY, AND CHAIRMAN OF THE ANAVEX SCIENTIFIC ADVISORY BOARD TIME: DECEMBER 2, 4:35 PM PT  4:50 PM PT PRESENTATION #2 (P076) TITLE: ORAL BLARCAMESINE COMPARISON TO NORMAL COGNITIVE AGING: DEMONSTRATING ALIGNMENT WITH PRODROMAL COGNITIVE AGING TRAJECTORIES IN PRECISION MEDICINE PATIENT POPULATION PHASE IIB/III TRIAL  FOR EARLY ALZHEIMER'S DISEASE PATIENTS PRESENTER: AUDREY GABELLE, MD, PHD, PROFESSOR OF NEUROLOGY, NEUROLOGIST AND MEMBER OF THE ANAVEX SCIENTIFIC ADVISORY BOARD AND DOCTOR IN NEUROSCIENCES AT THE MEMORY RESOURCES RESEARCH CENTER, THE RARE AND EARLY DEMENTIA REFERENCE CENTER AND THE EUROPEAN NEURODEGENERATIVE EXCELLENCE CENTER OF MONTPELLIER UNIVERSITY TIME: DECEMBER 1, 3:00 PM PT  DECEMBER 2, 5:30 PM PT PRESENTATION #3 (P084) TITLE: ADVANCING ALZHEIMER'S DISEASE CARE: CONVENIENCE FOR BOTH PATIENTS AND FAMILIES WITH ORAL BLARCAMESINE PRESENTER: MARWAN NOEL SABBAGH, MD, PROFESSOR OF NEUROLOGY, AND CHAIRMAN OF THE ANAVEX SCIENTIFIC ADVISORY BOARD TIME: DECEMBER 1, 3:00 PM PT  DECEMBER 2, 5:30 PM PT WE ARE EXCITED TO PRESENT, BACKED UP BY 

ANAVEX LIFE SCIENCES TO PRESENT ORAL BLARCAMESINE DATA AT THE 18TH CLINICAL TRIALS ON ALZHEIMER'S DISEASE (CTAD) CONFERENCE

COMPANY TO HOST A WEBCAST T ODAY AT 8:30 A.M. EASTERN TIME

ANAVEX LIFE SCIENCES REPORTS FISCAL 2025 FOURTH QUARTER FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

NEW YORK, NOV. 19, 2025 (GLOBE NEWSWIRE) -- ANAVEX LIFE SCIENCES CORP. (ANAVEX OR THE COMPANY) (NASDAQ: AVXL), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING INNOVATIVE TREATMENTS FOR ALZHEIMER'S DISEASE, PARKINSON'S DISEASE, SCHIZOPHRENIA, NEURODEVELOPMENTAL, NEURODEGENERATIVE, AND RARE DISEASES, INCLUDING RETT SYNDROME, AND OTHER CENTRAL NERVOUS SYSTEM (CNS) DISORDERS, TODAY ANNOUNCED THAT IT WILL PRESENT AT THE 44TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE ON WEDNESDAY, JANUARY 14TH 2026, AT THE WESTIN ST. FRANCIS IN SAN FRANCISCO, CA. CHRISTOPHER U MISSLING, PHD, PRESIDENT & CHIEF EXECUTIVE OFFICER WILL PRESENT THE COMPANY IN A SESSION SCHEDULED 4:30 PM  5:10 PM (PACIFIC TIME).

ANAVEX LIFE SCIENCES TO PRESENT AT THE 44TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE

NEW YORK , NOV. 18, 2025 /PRNEWSWIRE/ -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF ANAVEX LIFE SCIENCES CORP. ("ANAVEX" OR THE "COMPANY") (NASDAQ: AVXL).SUCH INVESTORS ARE ADVISED TO CONTACT DANIELLE PEYTON AT NEWACTION@POMLAW.COMOR 646-581-9980, EXT.

WEBCAST AND CONFERENCE CALL TO BE HELD TUESDAY, NOVEMBER 25, 2025, 8:30 AM ET WEBCAST AND CONFERENCE CALL TO BE HELD TUESDAY, NOVEMBER 25, 2025, 8:30 AM ET

ANAVEX LIFE SCIENCES TO ANNOUNCE FISCAL 2025 FOURTH QUARTER FINANCIAL RESULTS ON TUESDAY, NOVEMBER 25, 2025

COMPANY PLANS TO REQUEST RE-EXAMINATION AFTER CHMP OPINION FEEDBACK FOLLOWING ITS ORAL EXPLANATION FDA ADVISES COMPANY TO MEET AND DISCUSS COMPANY'S ALZHEIMER'S DISEASE CLINICAL TRIAL RESULTS NEW YORK, NOV. 14, 2025 (GLOBE NEWSWIRE) -- ANAVEX LIFE SCIENCES CORP. (ANAVEX OR THE COMPANY) (NASDAQ: AVXL), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING INNOVATIVE TREATMENTS FOR ALZHEIMER'S DISEASE, PARKINSON'S DISEASE, SCHIZOPHRENIA, NEURODEVELOPMENTAL, NEURODEGENERATIVE, AND RARE DISEASES, INCLUDING RETT SYNDROME, AND OTHER CENTRAL NERVOUS SYSTEM (CNS) DISORDERS, TODAY PROVIDES A REGULATORY UPDATE ON BLARCAMESINE FOR EARLY ALZHEIMER'S DISEASE. THE COMPANY WAS INFORMED BY THE COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) OF THE EUROPEAN MEDICINES AGENCY (EMA) OF A NEGATIVE TREND VOTE ON THE MARKETING AUTHORISATION APPLICATION (MAA) FOR BLARCAMESINE FOLLOWING ITS CHMP ORAL EXPLANATION.

ANAVEX LIFE SCIENCES PROVIDES REGULATORY UPDATE ON BLARCAMESINE FOR EARLY ALZHEIMER'S DISEASE

ADAS-COG13 DIFFERENCE 12.78 (P < 0.0001) WITH ORAL BLARCAMESINE TREATMENT COMPARED TO ADNI CONTROL GROUP AT WEEK 144

ANAVEX LIFE SCIENCES ANNOUNCES CONTINUED LONG-TERM BENEFIT FROM ORAL BLARCAMESINE COMPARED TO DECLINE OBSERVED IN THE ALZHEIMER'S DISEASE NEUROIMAGING INITIATIVE (ADNI) CONTROL GROUP

Anavex Life Sciences Corp.

AVXL

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Anavex Life Sciences Corp.

AVXL.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

AVXL